Krishnan L, Dicaire C J, Patel G B, Sprott G D
Institute for Biological Sciences, National Research Council of Canada, Ottawa, Ontario, Canada K1A 0R6.
Infect Immun. 2000 Jan;68(1):54-63. doi: 10.1128/IAI.68.1.54-63.2000.
Ether glycerolipids extracted from various archaeobacteria were formulated into liposomes (archaeosomes) possessing strong adjuvant properties. Mice of varying genetic backgrounds, immunized by different parenteral routes with bovine serum albumin (BSA) entrapped in archaeosomes ( approximately 200-nm vesicles), demonstrated markedly enhanced serum anti-BSA antibody titers. These titers were often comparable to those achieved with Freund's adjuvant and considerably more than those with alum or conventional liposomes (phosphatidylcholine-phosphatidylglycerol-cholesterol, 1. 8:0.2:1.5 molar ratio). Furthermore, antigen-specific immunoglobulin G1 (IgG1), IgG2a, and IgG2b isotype antibodies were all induced. Association of BSA with the lipid vesicles was required for induction of a strong response, and >80% of the protein was internalized within most archaeosome types, suggesting efficient release of antigen in vivo. Encapsulation of ovalbumin and hen egg lysozyme within archaeosomes showed similar immune responses. Antigen-archaeosome immunizations also induced a strong cell-mediated immune response: antigen-dependent proliferation and substantial production of cytokines gamma interferon (Th1) and interleukin-4 (IL-4) (Th2) by spleen cells in vitro. In contrast, conventional liposomes induced little cell-mediated immunity, whereas alum stimulated only an IL-4 response. In contrast to alum and Freund's adjuvant, archaeosomes composed of Thermoplasma acidophilum lipids evoked a dramatic memory antibody response to the encapsulated protein (at approximately 300 days) after only two initial immunizations (days 0 and 14). This correlated with increased antigen-specific cell cycling of CD4(+) T cells: increase in synthetic (S) and mitotic (G(2)/M) and decrease in resting (G(1)) phases. Thus, archaeosomes may be potent vaccine carriers capable of facilitating strong primary and memory humoral, and cell-mediated immune responses to the entrapped antigen.
从多种古细菌中提取的醚甘油脂质被制备成具有强佐剂特性的脂质体(古脂质体)。用包裹在古脂质体(约200纳米大小的囊泡)中的牛血清白蛋白(BSA)通过不同的非肠道途径免疫具有不同遗传背景的小鼠,其血清抗BSA抗体滴度显著提高。这些滴度通常与使用弗氏佐剂所达到的滴度相当,且远高于使用明矾或传统脂质体(磷脂酰胆碱 - 磷脂酰甘油 - 胆固醇,摩尔比为1.8:0.2:1.5)所达到的滴度。此外,还诱导产生了抗原特异性免疫球蛋白G1(IgG1)、IgG2a和IgG2b同种型抗体。诱导强烈反应需要BSA与脂质囊泡结合,并且在大多数类型的古脂质体中,>80%的蛋白质被内化,这表明抗原在体内能有效释放。在古脂质体内包裹卵清蛋白和鸡卵溶菌酶显示出类似的免疫反应。抗原 - 古脂质体免疫还诱导了强烈的细胞介导免疫反应:体外培养时,脾细胞出现抗原依赖性增殖以及大量产生细胞因子γ干扰素(Th1)和白细胞介素 - 4(IL - 4)(Th2)。相比之下,传统脂质体几乎不诱导细胞介导免疫,而明矾仅刺激产生IL - 4反应。与明矾和弗氏佐剂不同,由嗜酸嗜热放线菌脂质组成的古脂质体在仅进行两次初始免疫(第0天和第14天)后,在大约300天时对包裹的蛋白质引发了显著的记忆抗体反应。这与CD4(+) T细胞抗原特异性细胞周期增加相关:合成期(S)和有丝分裂期(G(2)/M)增加,静止期(G(1))减少。因此,古脂质体可能是强大的疫苗载体,能够促进对包裹抗原产生强烈的初次和记忆性体液免疫以及细胞介导免疫反应。
Hum Vaccin Immunother. 2017-5-24
Crit Rev Biotechnol. 1999
FEMS Microbiol Lett. 1997-9-1
Hum Vaccin Immunother. 2024-12-31
Pharmaceutics. 2023-8-9
J Nanobiotechnology. 2022-7-26
Methods Mol Biol. 2022
Immunol Today. 1999-2
J Leukoc Biol. 1998-12
Immunol Today. 1998-7
Annu Rev Immunol. 1998